'Biosimilar Lantus' filed in the US
This article was originally published in Scrip
Executive Summary
The US FDA has accepted the filing of a new drug application for the biosimilar LY2963016, Eli Lilly and Boehringer Ingelheim's basal (long-acting) insulin analog for the treatment of type 1 and type 2 diabetes.